MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, "Opthea”, the "Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLORetina aims to provide cutting-edge insights on research and clinical development from world-leading experts in the field of medical retina, retinal surgery, and imaging.

Details are as follows:

Session:Retina Futura 1: Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates
Date:Friday, December 6, 2024, 11:25 AM CET
Presentation:Beyond VEGF-A Inhibition: Will Blocking VEGF-C and VEGF-D Lead to Better Outcomes?
Presenter:Professor Adnan Tufail, MBBS, MD, FRCOphth
Program:https://floretina.com/floretinaicoormeeting2024/program
  
About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

Investor Inquiries

PJ Kelleher 

LifeSci Advisors, LLC 

Email: [email protected]

Phone: 617-430-7579 

Media Inquiries

Silvana Guerci-Lena

NorthStream Global Partners

Email: [email protected]

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399, Email: [email protected] Web: www.opthea.com

Source: Opthea Limited